Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) represents the majority of liver cancer and is the fourth most common cause of cancer‐related death. Although advances in molecular targeted therapy have shown promise, none of these agents has yet demonstrated significant clinical benefit. Bromo‐ and extraterminal dom...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Liu, Chen, Miao, Xiaolong, Wang, Yao, Wen, Liang, Cheng, Xiawei, Kong, Deqiang, Zhao, Pengwei, Song, Dandan, Wang, Xinyi, Ding, Xianfeng, Xia, Hongguang, Wang, Weilin, Sun, Qiming, Gong, Weihua
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Basic and Clinical Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540980/
https://ncbi.nlm.nih.gov/pubmed/32726482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14588
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars